Search results
Michigan insurer plans to drop coverage for weight loss drugs
The Hill· 2 days agoBlue Cross Blue Shield of Michigan is one such insurer. Companies aren’t entirely rejecting the drug...
Forget Nvidia. Meet the Ultimate Artificial Intelligence (AI) Growth Investment
The Motley Fool via AOL· 11 hours agoThe 10 stocks that made the cut could produce monster returns in the coming years. Consider when...
3 Healthcare Dividend Stocks to Buy Now
TheStreet.com· 1 day agoThe healthcare sector offers an opportunity for long-term growth and dividends, with these three companies at the top of our list. The U.S. healthcare...
FTC Warns Pharma Companies It Means Business with Its Orange Book Listing Policy | JD Supra
JD Supra· 5 days agoPolicy differences are endemic in politics, and the phrase "causing more heat than light" regarding federal drug policy comes readily to mind listening to the rhetoric coming ...
Will Walmart Reach a Trillion-Dollar Market Cap by 2030?
Motley Fool via Yahoo Finance· 10 hours agoEither way, Walmart stock is still a great investment prospect in the meantime even if it's not apt...
Feds said drug money fueled Miami firm’s real estate buying spree, but nobody was charged
Miami Herald via Yahoo Finance· 6 days ago“Sometimes there just isn’t enough evidence about any one person,” he said. In response to a...
People Are Remembering Wild And Newsworthy Events That Happened In 2001 But Were Forgotten Because...
BuzzFeed via Yahoo News· 10 hours ago"Michael Jackson just finished the weekend reuniting with his brothers for a pair of sold-out shows...
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Motley Fool via Yahoo Finance· 1 day agoConsider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk,...
Zacks via Yahoo Finance· 6 days agoToday's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S,...
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with...
KSAN - KLST San Angelo· 6 days agoProduct Administration (NMPA) has approved a global registrational Phase III study of the company's novel drug candidate olverembatinib (HQP1351), in patients ...